Triglycerides, Long Chain; Triglycerides, Medium Chain
Ketogenic diet for intractable seizures, glucose transport protein defect, or pyruvate dehydrogenase deficiency (long chain); dietary management of conditions requiring medium chain triglycerides including chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, and fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).
Access path
- Mar 2017Recommended
- PBS listing · Restricted
From the public summary
6.1 The PBAC noted the change to the listings processed by the secretariat. 3PSD · Mar 2017
Cost-effectiveness
not-modelled — minor submission for formulation/product-form change with no economic evaluation
Decision context
PopulationPatients with intractable seizures requiring ketogenic diet; glucose transport protein defect; pyruvate dehydrogenase deficiency (long chain); chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, or fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders (medium chain).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2017 | Recommended | — | — | Other |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC specifies particular medical conditions (intractable seizures, genetic disorders, specific malabsorption causes) versus broad TGA label covering all foods for special medical purposes.